IMUNAR

IMUNAR has developed a cancer biotreatment T1-IR TM consisting to provide the missing cytokines directly in the tumor to activate the cancer-fighting immune cells to eliminate the tumor mass... There are eight million Americans currently battling cancer. And there is 2.4 million new patients seeking cancer treatment annually in the U.S.A. Forty-three percent of these patients will die within 5 years. There is a crucial need for better therapy. IMUNAR ™s T1-IR TM has been granted patents in the U.S.A., Europe, Mexico, Singapore and soon in Canada. We are dedicated to bring this novel cancer therapy to cancer patients as rapidly as possible.